[Effect of the administration of Cardiostenol on experimental hepatitis in mice induced with MHV-3 virus].
Treatment with Cardiostenol (commercial name of a pharmaceutical product containing morphine chloridrate+atropine+sparteine) does not modify the course of hepatitis in mice infected with MHV-3 virus. Similar results were previously obtained by treatment with morphine chloridrate alone.
D000818:Animals; D001285:Atropine / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D006524:Hepatitis, Viral, Animal / Q000188:drug therapy*; D051379:Mice; D009020:Morphine / Q000627:therapeutic use*; D006517:Murine hepatitis virus / Q000187:drug effects; D013034:Sparteine / Q000627:therapeutic use*
D004338:Drug Combinations; C030674:atropine, morphine drug combination; D013034:Sparteine; D009020:Morphine; D001285:Atropine
Effetto della somministrazione di Cardiostenol sulla epatite sperimentale del topo da virus MHV-3.